The University of Southampton
University of Southampton Institutional Repository

S77 the idiopathic pulmonary fibrosis patients reported outcome measure (IPF-PROM) is reliable and valid for use in populations with IPF

S77 the idiopathic pulmonary fibrosis patients reported outcome measure (IPF-PROM) is reliable and valid for use in populations with IPF
S77 the idiopathic pulmonary fibrosis patients reported outcome measure (IPF-PROM) is reliable and valid for use in populations with IPF
Introduction: the IPF-PROM has been developed using rigorous patient-centred and psychometric methods. Triangulated qualitative approaches generated items that were relevant and specific to IPF populations. The 12-item questionnaire has 4-domains which measure the physical and psychological experiences of breathlessness, emotional well-being and energy levels.

Methods: a new population of eight-five patients with IPF recruited from five NHS centres participated in the 12 month IPF-PROM validation study; serial questionnaires were completed 3 monthly. Mean age 75.3±8 years. Baseline FVC 74.18% predicted (±16.14); DLCO 39.21% predicted (±14.43) and BMI 26.98 (±4.73). Content and face validity of the IPF-PROM were qualitatively assessed. Construct Validity was confirmed by principle components analysis (PCA); concurrent validity was assessed by correlations with FVC, SGRQ and EQ-5D-L VAS using Pearson’s correlation coefficient (r) and with MRC dyspnoea grade and EQ5D domains using Spearman’s coefficient (R2).

Results: the IPF-PROM has very good test-retest reliability. The median timeframe between time-point one and two was 19 days. The intra-class correlation coefficients (ICC) were all >0.8. Domain-1 0.835 (p=0.209); Domain-2 0.895 (p=0.150); Domian-3 0.813 (p=0.786) Domain-4 0.863 (p=0.761) Total 9.2 (p 0.784) Internal Reliability was further tested using Cronbach’s alpha (α). Domain-1 α=0.874; Domain-2 α=0.870; Domain-3 α=0.900; Domain-4 α=0.849 and total α=0.920. Sixty patients completed 12 months of the study; fifteen patients (17%) died and ten patients (11%) discontinued their involvement for reasons unknown. PCA confirmed a two factor model with eigen values>1.0 accounting for 75% of variance. All 12-items had a factor loading >0.5. The IPF-PROM correlates strongly with MRC; SGRQ; EQ-5D-L and moderately significantly with FVC. See table 1.

Discussion: the IPF PROM is reliable and valid for use. Longitudinal validation studies are challenging due to the uncertain trajectory and mortality associated with IPF. Additional studies are ongoing to affirm the responsiveness of the IPF-PROM. The IPF-PROM is available in other European languages.
0040-6376
A47-A47
Russell, A.M.
a64d7f4c-d4c0-488b-b66a-4c8fe67f9822
Wickremasinghe, M
8f891dd3-57c5-4047-95a2-2cb32dcc6bf3
Renzoni, E.
d1dae957-aa07-4d68-b12c-c0842eb1cd0d
Adamali, H.
aafdad02-2c6d-4ae2-9239-f197049a93fe
Borril, Z.
1138430f-3707-477a-b7e7-b4b57a6f3f83
Fletcher, Sophie
71599088-9df7-4d4a-8570-aef773ead0fe
Maher, T.M.
c6f3810d-d7bb-44d2-a58f-86300ad5aa2d
Ng Man Kwong, G.
d4d03436-f333-4954-9206-9d6dc39b9805
Saketkoo, L.A.
1a242c3f-3384-4e5f-b27f-49f47fa10c40
Fleming, S.
e696bc95-7ae3-42ea-980c-65c3817a3ee4
Cullinan, P.
dc367687-756e-4bef-af32-8fd2ff2023a7
Russell, A.M.
a64d7f4c-d4c0-488b-b66a-4c8fe67f9822
Wickremasinghe, M
8f891dd3-57c5-4047-95a2-2cb32dcc6bf3
Renzoni, E.
d1dae957-aa07-4d68-b12c-c0842eb1cd0d
Adamali, H.
aafdad02-2c6d-4ae2-9239-f197049a93fe
Borril, Z.
1138430f-3707-477a-b7e7-b4b57a6f3f83
Fletcher, Sophie
71599088-9df7-4d4a-8570-aef773ead0fe
Maher, T.M.
c6f3810d-d7bb-44d2-a58f-86300ad5aa2d
Ng Man Kwong, G.
d4d03436-f333-4954-9206-9d6dc39b9805
Saketkoo, L.A.
1a242c3f-3384-4e5f-b27f-49f47fa10c40
Fleming, S.
e696bc95-7ae3-42ea-980c-65c3817a3ee4
Cullinan, P.
dc367687-756e-4bef-af32-8fd2ff2023a7

Russell, A.M., Wickremasinghe, M, Renzoni, E., Adamali, H., Borril, Z., Fletcher, Sophie, Maher, T.M., Ng Man Kwong, G., Saketkoo, L.A., Fleming, S. and Cullinan, P. (2018) S77 the idiopathic pulmonary fibrosis patients reported outcome measure (IPF-PROM) is reliable and valid for use in populations with IPF. Thorax, 73, A47-A47. (doi:10.1136/thorax-2018-212555.83).

Record type: Meeting abstract

Abstract

Introduction: the IPF-PROM has been developed using rigorous patient-centred and psychometric methods. Triangulated qualitative approaches generated items that were relevant and specific to IPF populations. The 12-item questionnaire has 4-domains which measure the physical and psychological experiences of breathlessness, emotional well-being and energy levels.

Methods: a new population of eight-five patients with IPF recruited from five NHS centres participated in the 12 month IPF-PROM validation study; serial questionnaires were completed 3 monthly. Mean age 75.3±8 years. Baseline FVC 74.18% predicted (±16.14); DLCO 39.21% predicted (±14.43) and BMI 26.98 (±4.73). Content and face validity of the IPF-PROM were qualitatively assessed. Construct Validity was confirmed by principle components analysis (PCA); concurrent validity was assessed by correlations with FVC, SGRQ and EQ-5D-L VAS using Pearson’s correlation coefficient (r) and with MRC dyspnoea grade and EQ5D domains using Spearman’s coefficient (R2).

Results: the IPF-PROM has very good test-retest reliability. The median timeframe between time-point one and two was 19 days. The intra-class correlation coefficients (ICC) were all >0.8. Domain-1 0.835 (p=0.209); Domain-2 0.895 (p=0.150); Domian-3 0.813 (p=0.786) Domain-4 0.863 (p=0.761) Total 9.2 (p 0.784) Internal Reliability was further tested using Cronbach’s alpha (α). Domain-1 α=0.874; Domain-2 α=0.870; Domain-3 α=0.900; Domain-4 α=0.849 and total α=0.920. Sixty patients completed 12 months of the study; fifteen patients (17%) died and ten patients (11%) discontinued their involvement for reasons unknown. PCA confirmed a two factor model with eigen values>1.0 accounting for 75% of variance. All 12-items had a factor loading >0.5. The IPF-PROM correlates strongly with MRC; SGRQ; EQ-5D-L and moderately significantly with FVC. See table 1.

Discussion: the IPF PROM is reliable and valid for use. Longitudinal validation studies are challenging due to the uncertain trajectory and mortality associated with IPF. Additional studies are ongoing to affirm the responsiveness of the IPF-PROM. The IPF-PROM is available in other European languages.

This record has no associated files available for download.

More information

e-pub ahead of print date: 30 November 2016
Published date: 16 November 2018

Identifiers

Local EPrints ID: 486022
URI: http://eprints.soton.ac.uk/id/eprint/486022
ISSN: 0040-6376
PURE UUID: 96c4d82c-a8c9-4a93-9acc-44028a90a8d6
ORCID for Sophie Fletcher: ORCID iD orcid.org/0000-0002-5633-905X

Catalogue record

Date deposited: 05 Jan 2024 18:00
Last modified: 21 Sep 2024 02:15

Export record

Altmetrics

Contributors

Author: A.M. Russell
Author: M Wickremasinghe
Author: E. Renzoni
Author: H. Adamali
Author: Z. Borril
Author: Sophie Fletcher ORCID iD
Author: T.M. Maher
Author: G. Ng Man Kwong
Author: L.A. Saketkoo
Author: S. Fleming
Author: P. Cullinan

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×